Over the last several decades, substantial treatment advances have improved the quality of life and median predicted survival in people with cystic fibrosis (PwCF). It is critical for CF clinicians to begin to discuss health considerations related to an aging and overall healthier CF population. Such considerations include family planning, reproductive health, and contraception. CF care teams are trusted sources of medical information and therefore often have initial discussions related to contraception for PwCF. The purpose of this article is to review the available pharmacologic contraceptive methods, with a specific focus on the benefits and risks that may be more relevant to PwCF.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcf.2024.01.003DOI Listing

Publication Analysis

Top Keywords

people cystic
8
cystic fibrosis
8
pharmacologic contraception
4
contraception methods
4
methods people
4
fibrosis practical
4
practical review
4
review clinicians
4
clinicians decades
4
decades substantial
4

Similar Publications

We present a clinical observation of an 18-year-old female patient with congenital bronchiectasis combined with congenital cystic degeneration of the upper lobes of both lungs, Williams-Campbell syndrome, long-COVID, severe course. The patient was treated in infectious disease department (three times), with subsequent transfer to pulmonology department of Kursk Regional Multi-Purpose Clinical Hospital from 31.01.

View Article and Find Full Text PDF

A spontaneous pneumothorax may be the heralding manifestation of diffuse cystic lung disease (DCLD). Historically, these diagnoses were differentiated by unique clinical, radiographic and tissue pathology characteristics. With recent advancements in genomics, several forms of DCLD can now be diagnosed through genetic testing and patients can thereby avoid undergoing an invasive lung biopsy.

View Article and Find Full Text PDF

Background: Gastric duplication (GD) is a rare congenital gastrointestinal malformation, and usually identified in childhood. This study aimed to investigate the clinical characteristics and treatment of GDs in children.

Methods: A retrospective review was conducted of medical records of 38 patients with the diagnosis of GD, treated in the Department of General Surgery, Children's Hospital of Zhejiang University School of Medicine, within the period from August 2013 to December 2023.

View Article and Find Full Text PDF

Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a CFTR modulator therapy approved for people with cystic fibrosis (pwCF) who have at least one phe508del mutation. However, its approval in the European Union (EU) for pwCF with non-phe508del mutations is lacking, because data on treatment response in this subgroup are scarce. This retrospective observational study evaluated six pwCF (ages 6 to 66) with responsive CFTR mutations (M1101K, R347P, 2789+5G>A, G551D) undergoing off-label ETI therapy.

View Article and Find Full Text PDF

Ruptured Ovarian Mature Cystic Teratoma with Adenocarcinoma Transformation: A Case Report.

Int J Womens Health

December 2024

Department of Gynecology, Rizhao People's Hospital, Rizhao, Shandong Province, 276800, People's Republic of China.

Purpose: Ovarian mature cystic teratoma (MCT) is the most common ovarian tumor, and only a small fraction undergoes malignant transformation. The most prevalent malignant type of the ovary is squamous cell carcinoma, followed by adenocarcinoma. However, ruptured ovarian mature cystic teratoma with adenocarcinoma transformation is extremely rare.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!